CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 416 enrolled
Drug / intervention
Antiarrythmic Drug Therapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02830360
NCT02830360Phase 4Completed
CompareCT.gov

Ventricular Tachycardia Antiarrhythmics or AblatioN In Structural Heart Disease 2

John Sapp·interventional·Posted Jul 12, 2016·Updated Aug 1, 2024

In Brief

A Phase 4 clinical trial evaluating Antiarrythmic Drug Therapy and Catheter ablation for Ventricular Tachycardia (VT). Completed, enrolled 416 participants across 22 sites in 3 countries.

Detailed Summary

A multicenter, randomized clinical trial to assess whether catheter ablation or antiarrhythmic drug therapy provides the most effective control of important clinical outcomes for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia (VT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVentricular Tachycardia (VT)
CountriesCanada, France, United States
CollaboratorsHeart and Stroke Foundation of Canada, Abbott Medical Devices, Biosense Webster, Inc., Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Cardiac Arrhythmia Network of Canada, Abbott, Nova Scotia Health Authority

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 12, 2016
Enrollment StartOct 1, 2016
Primary CompletionJun 6, 2024
Study CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 10.0 years ago

Interventions

Antiarrythmic Drug Therapydrug

Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)

Catheter ablationprocedure

Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.